
FDA grants lymphoma cancer treatment in dogs full approval
Fox News
The Food and Drug Administration (FDA) announced full approval for a lymphoma treatment in dogs on Thursday, aiming to benefit quality of life and allow pets and their owners more time together.
Lymphoma stems from abnormal growth of white blood cells, said to affect any organ but commonly begins in the lymph nodes, spleen and bone marrow. Signs of the disease in dogs can vary and its cause in dogs is unknown, per the FDA. A study involving 158 dogs "diagnosed with multicentric lymphoma with at least one enlarged peripheral lymph node," including at least 120 treated with Tanovea, saw an added 61 days of survival on average. Other results suggested the drug lent an additional 168 days to live with the disease without progressing in severity.More Related News